RECRUITINGINTERVENTIONAL
Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis
Contribution of Whole Body Muscle MRI for Early Diagnosis of Amyotrophic Lateral Sclerosis.
About This Trial
Nearly 60% of Amyotrophic Lateral Sclerosis (ALS) patients have a low level of diagnostic certainty (possible, probable) at the time of diagnosis. In the absence of biomarkers, this diagnosis is based, among other things, on the demonstration of the diffusion of signs of denervation by electroneuromyography (ENMG). The objective of this study is to improve the earliness and the level of diagnostic certainty by better demonstrating the diffusion of the denervation process by whole body muscular MRI.
Who May Be Eligible (Plain English)
Who May Qualify:
- Consent form signed by the patient
- Patients suspected ALS defined according Awaji Shima criteria (possible, probable, defined)
- Clinical assessment of upper motor neuron involvement
- Electrophysiologic assessment of lower motor neuron involvement
Who Should NOT Join This Trial:
- inability to give willing to sign a consent form
- a contraindication to MRI
- respiratory failure impairing ability to lie flat in the scanner.
- Patient placed under judicial protection or under another protective regime,
- Females who are pregnant
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Consent form signed by the patient
* Patients suspected ALS defined according Awaji Shima criteria (possible, probable, defined)
* Clinical assessment of upper motor neuron involvement
* Electrophysiologic assessment of lower motor neuron involvement
Exclusion Criteria:
* inability to give informed consent
* a contraindication to MRI
* respiratory failure impairing ability to lie flat in the scanner.
* Patient placed under judicial protection or under another protective regime,
* Females who are pregnant
Treatments Being Tested
DIAGNOSTIC_TEST
Whole Body MRI and ENMG
Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
Locations (1)
Pascal CINTAS
Toulouse, France